<DOC>
	<DOC>NCT02115152</DOC>
	<brief_summary>This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).</brief_summary>
	<brief_title>Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Females aged 1870 with histologically proven, corebiopsied, Stage IIIII invasive breast cancer No distant disease Inadequate heart or liver or kidney function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Neoadjuvant therapy</keyword>
	<keyword>Early Breast Cancer</keyword>
</DOC>